Person:
ALİYEV, ALTAY

Loading...
Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
Organizational Unit
Job Title
First Name
ALTAY
Last Name
ALİYEV
Name
Email Address
Birth Date

Search Results

Now showing 1 - 3 of 3
Loading...
Thumbnail Image
PublicationOpen Access

Evaluation of Kidney Function in Patients on Chemotherapy

2021-04-01T00:00:00Z, Haziyev, Elgun, GÜRSU, Meltem, ŞEKER, Mesut, ELÇİOĞLU, Ömer Celal, ARTAN, AYŞE SERRA, ALİYEV, Altay, TÜRK, HACI MEHMET, DEMİR, Tarık, TOPRAK, ALİ, KAZANCIOĞLU, Rümeyza, GÜRSU, MELTEM, ŞEKER, MESUT, ELÇİOĞLU, ÖMER CELAL, ARTAN, AYŞE SERRA, ALİYEV, ALTAY, TÜRK, HACI MEHMET, DEMİR, TARıK, TOPRAK, ALİ, KAZANCIOĞLU, RÜMEYZA

Objective: We aimed to study whether long-term kidney function would be affected by different chemotherapy regimens in patients with malignancy.

No Thumbnail Available
PublicationMetadata only

Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients

2018-01-01, Seker, MESUT, ISEN, Hayati C., Cevirme, NİDAL, Aydin, Sinem, Bilici, Ahmet, COBAN, EZGİ, Bulut, HURİ, YASIN, Ayse I., Demir, TARIK, Aliyev, ALTAY, Kocyigit, ABDÜRRAHİM, Turk, Haci M., ŞEKER, MESUT, ÇEVİRME, NİDAL, BULUT, HURI, ÇOBAN, EZGİ, DEMİR, TARıK, ALİYEV, ALTAY, KOÇYİĞİT, ABDÜRRAHİM, TÜRK, HACI MEHMET

Background: The aim of this study was to identify the possible relationship of 5-fluorouracil (5-FU)-related arterial vasoconstriction with urotensin-2 (UT-2), which has a high potential as an endogenic vasoconstrictor. Methods: We assigned the patients to 1 of 3 groups. Patients in group 1 received a bolus of 5-FU, those in group 2 a continuous infusion (CI) of 5-FU, and those in group 3 no 5-FU, which was also a control group. Pre- and post-treatment UT-2 levels and brachial arterial diameters were measured and recorded in all patients. Results: 132 patients were included in the study. Pre-and post-treatment brachial artery diameters were similar in all groups: in group 1 (3.28 +/- 0.52 vs. 3.25 +/- 0.44 mm, p = 0.740), in group 2 (3.57 +/- 0.47 vs. 3.46 +/- 0.45 mm, p = 0.441) and in the control group (3.51 +/- 0.52 vs. 3.25 +/- 0.44 mm, p = 0.818). Pre-and post-treatment UT-2 levels were significantly different in each group: in group 1 (39.5 +/- 30.9 vs. 56.7 +/- 27.1 ng/ml, p = 0.0001), in group 2 (37.7 +/- 33.7 vs. 62.5 +/- 37.7 ng/ml, p = 0.0001) and in the control group (52.9 +/- 40.2 vs. 60.8 +/- 40.7 ng/ml, p = 0.006). Conclusion: Our findings suggest that UT-2 has a high potential as a vasoconstrictor agent in our bodies and its level increases through a bolus or CI 5-FU. Increased UT-2 levels are likely to play a role in 5-FU-related cardiac toxicity pathogenesis. (c) 2018 S. Karger GmbH, Freiburg

Loading...
Thumbnail Image
PublicationOpen Access

Primitive Neuroectodermal Tumor of the Testis

2021-11-01T00:00:00Z, DEMİR, Tarık, ALİYEV, Altay, ŞEKER, Mesut, ERSÖZ, CEVPER, ÇOBAN, GANİME, TÜRK, HACI MEHMET, DEMİR, TARıK, ALİYEV, ALTAY, ŞEKER, MESUT, ERSÖZ, CEVPER, ÇOBAN, GANİME, TÜRK, HACI MEHMET

A 21-year male presenting with left testicular mass and retroperitoneal lymphadenopathy underwent radical orchiectomy; and his pathological examination showed a mixed germ cell tumor composed of primitive neuroectodermal tumor mixed with mature teratoma. Six cycles of IE (ifosfamide, etoposide) and VAC (vincristine, doxorubicin, cyclophosphamide) chemotherapy were given after sperm preservation. He then underwent retroperitoneal lymph node dissection (RPLND). No tumor was detected in the removed lymph nodes, and all lymph nodes were reported as showing reactive changes.